Oramed Pharmaceuticals, Inc. (ORMP.OB) is a company focused on the commercial development of proprietary oral therapies. Oramed’s main focus is the treatment of diabetes via an oral insulin capsule, which has the potential to help millions of diabetics worldwide. The Company’s oral insulin will better control diabetes by ingesting the capsule at an earlier stage of one’s treatment. Furthermore, based on Oramed’s patented technology, its top scientists are developing other methods of oral delivery for drugs and vaccinations that are currently not available in an oral form.
According to the World Health Organization, the global diabetic population exceeds 177 million patients worldwide. Insulin is administered to these patients through painful daily injections. Oramed Pharmaceuticals’ oral insulin product offers a pain-free alternative for diabetics.
In addition to the oral insulin, Oramed is in the process of registering an Israeli patent for another method of insulin delivery and is beginning pre-clinical testing of an oral replacement for the flu vaccine. Over one billion doses of the flu vaccine are administered in a year.
The Oramed research team consists of scientists with more than 25 years of clinical experience in leading research and development efforts.
Let us hear your thoughts: Oramed Pharmaceuticals, Inc. Message Board